These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Determination of telomerase activity and telomere length. Wu KD; Moore MA Methods Mol Med; 2005; 113():207-23. PubMed ID: 15968105 [TBL] [Abstract][Full Text] [Related]
23. Telomerase as an anti-cancer target: current status and future prospects. Neidle S; Kelland LR Anticancer Drug Des; 1999 Aug; 14(4):341-7. PubMed ID: 10625926 [TBL] [Abstract][Full Text] [Related]
26. [Progress in telomerase and the inhibitors]. Zhou Y; Gong XG Sheng Wu Gong Cheng Xue Bao; 2001 Nov; 17(6):604-7. PubMed ID: 11910748 [TBL] [Abstract][Full Text] [Related]
27. Telomere maintenance as a target for anticancer drug discovery. Neidle S; Parkinson G Nat Rev Drug Discov; 2002 May; 1(5):383-93. PubMed ID: 12120414 [TBL] [Abstract][Full Text] [Related]
28. Telomerase as a diagnostic and therapeutic target for cancer. Doyle LA; Highsmith WE Expert Rev Anticancer Ther; 2002 Apr; 2(2):217-25. PubMed ID: 12113243 [TBL] [Abstract][Full Text] [Related]
29. Analysis of telomerase activity and telomere function in cancer. Gordon KE; Parkinson EK Methods Mol Biol; 2004; 281():333-48. PubMed ID: 15220541 [TBL] [Abstract][Full Text] [Related]
30. Telomeres and telomerase: Pharmacological targets for new anticancer strategies? Pendino F; Tarkanyi I; Dudognon C; Hillion J; Lanotte M; Aradi J; Ségal-Bendirdjian E Curr Cancer Drug Targets; 2006 Mar; 6(2):147-80. PubMed ID: 16529544 [TBL] [Abstract][Full Text] [Related]
31. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Chen Z; Koeneman KS; Corey DR Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918 [TBL] [Abstract][Full Text] [Related]
32. Telomerase as an emerging target to fight cancer--opportunities and challenges for nanomedicine. Philippi C; Loretz B; Schaefer UF; Lehr CM J Control Release; 2010 Sep; 146(2):228-40. PubMed ID: 20381558 [TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933 [TBL] [Abstract][Full Text] [Related]
34. Telomeres and telomerase: Biological and clinical importance in dogs. Nasir L Vet J; 2008 Feb; 175(2):155-63. PubMed ID: 17398127 [TBL] [Abstract][Full Text] [Related]
35. Telomerase inhibitors as anticancer therapy. Akiyama M; Hideshima T; Munshi NC; Anderson KC Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):567-75. PubMed ID: 12678724 [TBL] [Abstract][Full Text] [Related]
36. Telomere maintenance mechanisms as a target for drug development. Bearss DJ; Hurley LH; Von Hoff DD Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649 [TBL] [Abstract][Full Text] [Related]
37. Targeting the telosome: therapeutic implications. Folini M; Gandellini P; Zaffaroni N Biochim Biophys Acta; 2009 Apr; 1792(4):309-16. PubMed ID: 19419699 [TBL] [Abstract][Full Text] [Related]
38. The cytotoxic effects of single-stranded telomere mimics on OMA-BL1 cells. Page TJ; Mata JE; Bridge JA; Siebler JC; Neff JR; Iversen PL Exp Cell Res; 1999 Oct; 252(1):41-9. PubMed ID: 10502398 [TBL] [Abstract][Full Text] [Related]
39. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Zhang W; Piatyszek MA; Kobayashi T; Estey E; Andreeff M; Deisseroth AB; Wright WE; Shay JW Clin Cancer Res; 1996 May; 2(5):799-803. PubMed ID: 9816233 [TBL] [Abstract][Full Text] [Related]
40. Telomeres and telomerase as targets for cancer therapy. Zimmermann S; Martens UM Cell Mol Life Sci; 2007 Apr; 64(7-8):906-21. PubMed ID: 17310277 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]